GlassScriptPhysician profile
Kathryn C Eisermann Rogers
NPI 1306865472
$4,606.20
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $529 · 2021: $908 · 2022: $940 · 2023: $1,051 · 2024: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.76 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $878.91 | 2019-2024 | Trelegy Ellipta, Nucala |
| Kaleo, INC. | $734.15 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $610.49 | 2020-2024 | |
| Regeneron Healthcare Solutions, INC. | $442.48 | 2019-2024 | Dupixent |
| Genzyme Corporation | $258.63 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.16 | 2020-2023 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $184.16 | 2020-2023 | Airsupra, Fasenra |
| Alk-Abello, INC | $179.57 | 2019-2022 | |
| Csl Behring | $176.87 | 2022-2024 | Haegarda, Hizentra |
| Pfizer INC. | $172.31 | 2020-2024 | |
| Pharming Healthcare, INC. | $139.22 | 2021-2023 | Ruconest |
| Novartis Pharmaceuticals Corporation | $136.58 | 2021-2024 | |
| Intersect Ent, INC. | $75.81 | 2021 | |
| Biocryst US Sales Co., LLC | $66.85 | 2023-2024 | Orladeyo |
| Grifols USA, LLC | $56.09 | 2023-2024 | Xembify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $54.96 | 2019 | |
| Aimmune Therapeutics, INC. | $38.95 | 2022 | |
| Incyte Corporation | $29.85 | 2021 | |
| Adma Biomanufacturing LLC | $22.68 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $21.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $20.44 | 2020 | |
| Hikma Pharmaceuticals USA | $17.50 | 2024 | Ryaltris |
| Uswm, LLC | $16.82 | 2021 | |
| Abbvie INC. | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Eisermann Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.